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Background
The phase II DNA prime, rAd5 boost vaccine (HVTN
204) exhibited sufficient safety and immunogenicity to
advance into a phase IIb efficacy trial (HVTN 505) in Ad5
seronegative volunteers in the US. In the RV144 ALVAC
prime, A/E gp120 protein boost trial, levels of V1V2 IgG
antibodies significantly correlated with decreased risk of
infection.
Methods
Sera from 203 vaccinees receiving VRC-HIVDNA016-00-
VP DNA (m 0,1,2), and VRC-HIVADV014-00-VP rAd5
(m 6), at two weeks post rAd5 boost, and 208 placebos
were examined for binding gp140 and gp120 recombinant
proteins, gp41, and an antigen panel of 16 V1V2 IgG scaf-
folds representing clades A, B and C V1V2 sequences. A
subset of vaccinees and placebo was screened for binding
CD4BS antigens. Monoclonal antibodies were generated
from antigen specific memory B cell sorts and tested for
binding, neutralization, ADCC and virion capture.
Results
Clade A and B V1V2 IgG antibodies were elicited in
38.4% and 19.2% of vaccinees, respectively. A clonal line-
age of 3 gp41 mAbs (CH69, CH70, CH71), and a V3-spe-
cific gp120 mAb (CH73) were generated from vaccinees.
The gp41 mAbs captured infectious HIV-1 transmitted/
founder viruses, while CH73 mediated ADCC activity
against subtypes B and C infected cells, neutralized
subtypes B and C tier 1A viruses, and bound multiple
Envs of subtypes A, B and C.
Conclusion
The phase II multi-clade DNA prime, rAd5 boost vaccine
regimen elicited antibody responses to multiple epitope
specificities, including V1V2, V3, and gp41. CH69-CH71
and CH73 mAbs represent the initial human mAbs from
HVTN 204 vaccine recipients, and reflect the functional
profile of vaccine-elicited antibodies. These data suggest
that the HVTN 505 Phase IIb efficacy study using this
same vaccine regimen may provide an opportunity to
examine a diversity of antibody specificities that have been
hypothesized as a correlate of HIV-1 infection risk.
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